Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Down's syndrome.

Roizen NJ, Patterson D.

Lancet. 2003 Apr 12;361(9365):1281-9. Review.

PMID:
12699967
2.
4.

Socioeconomic and state-level differences in prenatal diagnosis and live birth prevalence of Down's syndrome in the United States.

Khoshnood B, Pryde P, Blondel B, Lee KS.

Rev Epidemiol Sante Publique. 2003 Dec;51(6):617-27.

PMID:
14967994
5.

Using decision analysis to compare policies for antenatal screening for Down's syndrome.

Fletcher J, Hicks NR, Kay JD, Boyd PA.

BMJ. 1995 Aug 5;311(7001):351-6.

6.

[Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].

Kjaergaard S, Hahnemann JM, Skibsted L, Jensen LN, Sperling L, Zingenberg H, Kristiansen A, Brøndum-Nielsen K.

Ugeskr Laeger. 2008 Mar 31;170(14):1152-6. Danish.

PMID:
18405480
7.
8.

[A study on population-based prenatal screening and diagnosis of Down's syndrome in Jiangsu province].

Liu QL, Hu YL, Xu ZF, Wang LJ, Sun Q, Lin N, Xu XY, Liu Y, Zhang JW, Tong JS, Wang XH, He J.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Jun;27(3):340-2. doi: 10.3760/cma.j.issn.1003-9406.2010.0.023. Chinese.

PMID:
20533279
9.

Use of the disutility ratio in prenatal screening for Down's syndrome.

van der Meulen JH, Mol BW, Pajkrt E, van Lith JM, Voorn W.

Br J Obstet Gynaecol. 1999 Feb;106(2):108-15.

PMID:
10426675
10.

Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.

Lamlertkittikul S, Chandeying V.

J Med Assoc Thai. 2007 Oct;90(10):1970-6.

PMID:
18041410
11.

A population-based evaluation of the impact of antenatal screening for Down's syndrome in France, 1981-2000.

Khoshnood B, De Vigan C, Vodovar V, Goujard J, Goffinet F.

BJOG. 2004 May;111(5):485-90.

12.

Urinary beta-core human chorionic gonadotrophin: a new approach to Down's syndrome screening.

Cuckle HS, Iles RK, Chard T.

Prenat Diagn. 1994 Oct;14(10):953-8.

PMID:
7534925
13.

Adults with Down's syndrome: the prevalence of complications and health care in the community.

Henderson A, Lynch SA, Wilkinson S, Hunter M.

Br J Gen Pract. 2007 Jan;57(534):50-5.

14.

Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.

DiMaio MS, Baumgarten A, Greenstein RM, Saal HM, Mahoney MJ.

N Engl J Med. 1987 Aug 6;317(6):342-6.

PMID:
2439909
15.

Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.

Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA.

N Engl J Med. 1994 Apr 21;330(16):1114-8.

16.

Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.

Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN, Connor JM.

N Engl J Med. 1996 May 9;334(19):1231-6.

17.

Prenatal biochemical screening for Down's syndrome and neural tube defects.

Wald NJ, Kennard A.

Curr Opin Obstet Gynecol. 1992 Apr;4(2):302-7. Review.

PMID:
1373963
18.

The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia.

Cheffins T, Chan A, Haan EA, Ranieri E, Ryall RG, Keane RJ, Byron-Scott R, Scott H, Gjerde EM, Nguyen AM, Ford JH, Sykes S.

BJOG. 2000 Dec;107(12):1453-9.

19.

Antenatal screening for Down's syndrome with the quadruple test.

Wald NJ, Huttly WJ, Hackshaw AK.

Lancet. 2003 Mar 8;361(9360):835-6.

PMID:
12642052
20.

Supplemental Content

Support Center